Coagulation factor VII/F7 Protein, Human (406a.a, HEK293, His)

Coagulation factor VII (F7) initiates the extrinsic pathway of blood coagulation. As a circulating zymogen, F7 is activated to F7a through proteolysis induced by factor Xa, factor XIIa, factor IXa, or thrombin. In the presence of tissue factor and calcium ions, F7a catalyzes limited proteolysis of factor X, converting it to factor Xa. F7a can also convert factor IX to factor IXa, emphasizing its pivotal role in coagulation cascades. Coagulation factor VII/F7 Protein, Human (406a.a, HEK293, His) is the recombinant human-derived Coagulation factor VII/F7, expressed by HEK293 , with C-His labeled tag. The total length of Coagulation factor VII/F7 Protein, Human (406a.a, HEK293, His) is 406 a.a..

Coagulation factor VII (F7) plays a crucial role in initiating the extrinsic pathway of blood coagulation. As a serine protease circulating in the blood in its zymogen form, factor VII undergoes activation to factor VIIa through minor proteolysis induced by factor Xa, factor XIIa, factor IXa, or thrombin. In the presence of tissue factor and calcium ions, factor VIIa further catalyzes the limited proteolysis of factor X, converting it to factor Xa. Additionally, in the presence of tissue factor and calcium, factor VIIa is capable of converting factor IX to factor IXa, highlighting its pivotal function in the intricate cascade of coagulation processes.

Measured by its ability to cleave 100μM fluorogenic peptide substrate Boc-VPR-AMC (HY-P137784) in kinetic mode for 5 minutes. The specific activity is 105.77 pmol/min/µg.

Human

HEK293

C-6*His

P08709-1 (A61-P466)

2155  [NCBI]

ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP

approximately 55-65 kDa

Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized a 0.22 μm filtered solution of 50 mM Tris-HCL, 150 mM NaCl, pH 7.5, 8% trehalose.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.